Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1946 4
1947 6
1948 10
1949 5
1950 16
1951 19
1952 11
1953 19
1954 14
1955 22
1956 27
1957 32
1958 22
1959 32
1960 36
1961 23
1962 33
1963 22
1964 27
1965 13
1997 1
1999 1
2001 1
2002 3
2003 4
2005 1
2007 1
2008 2
2009 3
2010 23
2011 793
2012 2265
2013 2400
2014 2191
2015 2130
2016 2171
2017 2300
2018 2027
2019 950
2020 28
Text availability
Article attribute
Article type
Publication date

Search Results

15,511 results
Results by year
Filters applied: . Clear all
Page 1
Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
An S and Fu L. EBioMedicine 2018 - Review. PMID 30224312 Free PMC article.
PROteolysis-TArgeting Chimeras (PROTACs) exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins. ...
PROteolysis-TArgeting Chimeras (PROTACs) exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins
Targeted protein degradation in vivo with Proteolysis Targeting Chimeras: Current status and future considerations.
Watt GF, et al. Drug Discov Today Technol 2019 - Review. PMID 31200862
Proteolysis Targeting Chimeras (PROTACs) are a rapidly expanding new therapeutic modality inducing selective protein degradation and offering the potential of a differentiated pharmacological profile across multiple therapeutic areas. ...
Proteolysis Targeting Chimeras (PROTACs) are a rapidly expanding new therapeutic modality inducing selective protein degradation and
Small-Molecule PROTACS: New Approaches to Protein Degradation
Toure M and Crews CM. Angew Chem Int Ed Engl 2016 - Review. PMID 26756721
However, recent reports of small-molecule-based proteolysis-targeting chimeras (PROTACs) have demonstrated that this technology can effectively decrease the cellular levels of several protein classes....
However, recent reports of small-molecule-based proteolysis-targeting chimeras (PROTACs) have demonstrated that this technology can e …
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression.
Qin C, et al. J Med Chem 2018. PMID 30019901 Free PMC article.
We describe herein a structure-guided design of [1,4]oxazepines as a new class of BET inhibitors and our subsequent design, synthesis, and evaluation of proteolysis-targeting chimeric (PROTAC) small-molecule BET degraders. ...
We describe herein a structure-guided design of [1,4]oxazepines as a new class of BET inhibitors and our subsequent design, synthesis, and e …
15,511 results
Jump to page
Feedback